Botty Investors LLC raised its stake in Allergan PLC (NYSE:AGN) by 749.1% during the second quarter, Holdings Channel reports. The fund owned 9,000 shares of the company’s stock after buying an additional 7,940 shares during the period. Allergan PLC accounts for 1.2% of Botty Investors LLC’s investment portfolio, making the stock its 20th largest position. Botty Investors LLC’s holdings in Allergan PLC were worth $2,080,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. Barnett & Company Inc. acquired a new stake in shares of Allergan PLC during the first quarter valued at approximately $111,000. Trust Co. of Vermont increased its stake in shares of Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock valued at $126,000 after buying an additional 89 shares during the last quarter. Ropes Wealth Advisors LLC increased its stake in shares of Allergan PLC by 13.2% in the first quarter. Ropes Wealth Advisors LLC now owns 497 shares of the company’s stock valued at $133,000 after buying an additional 58 shares during the last quarter. Integrated Investment Consultants LLC increased its stake in shares of Allergan PLC by 35.2% in the second quarter. Integrated Investment Consultants LLC now owns 592 shares of the company’s stock valued at $137,000 after buying an additional 154 shares during the last quarter. Finally, Trust Department MB Financial Bank N A increased its stake in shares of Allergan PLC by 77.4% in the second quarter. Trust Department MB Financial Bank N A now owns 653 shares of the company’s stock valued at $198,000 after buying an additional 285 shares during the last quarter. 85.25% of the stock is currently owned by institutional investors and hedge funds.

Shares of Allergan PLC (NYSE:AGN) traded down 0.51% on Friday, reaching $245.19. 3,358,894 shares of the company’s stock traded hands. The firm has a market cap of $97.08 billion, a P/E ratio of 23.34 and a beta of 0.73. The company’s 50-day moving average price is $247.03 and its 200 day moving average price is $244.75. Allergan PLC has a one year low of $195.50 and a one year high of $322.68.

Allergan PLC (NYSE:AGN) last posted its quarterly earnings data on Monday, August 8th. The company reported $3.35 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.34 by $0.01. The firm earned $3.68 billion during the quarter, compared to analyst estimates of $4.10 billion. Allergan PLC had a net margin of 28.06% and a return on equity of 7.67%. The company’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same quarter last year, the business posted $4.41 EPS. On average, equities analysts forecast that Allergan PLC will post $14.01 EPS for the current fiscal year.

Several analysts recently commented on AGN shares. Cowen and Company reaffirmed a “buy” rating on shares of Allergan PLC in a research note on Tuesday, May 24th. Bank of America Corp. reissued a “buy” rating and issued a $294.00 price target (up previously from $287.00) on shares of Allergan PLC in a research note on Wednesday, June 29th. Leerink Swann reissued a “buy” rating on shares of Allergan PLC in a research note on Thursday, June 30th. Wells Fargo & Co. reissued a “buy” rating on shares of Allergan PLC in a research note on Friday, June 10th. Finally, Vetr downgraded Allergan PLC from a “strong-buy” rating to a “buy” rating and set a $275.94 price target on the stock. in a research note on Thursday, June 2nd. Six research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $308.54.

Allergan PLC Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

5 Day Chart for NYSE:AGN

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC (NYSE:AGN).

Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.